Abstract:Proteolysis-targeting chimeras (PROTACs) are essential bifunctional molecules that target proteins of interest (POIs) for degradation by cellular ubiquitination machinery. Despite significant progress made in understanding PROTACs' functions, their therapeutic potential remains largely untapped. As a result of the success of highly flexible, scalable, and low-cost mRNA therapies, as well as the advantages of the first generation of peptide PROTACs (p-PROTACs), we present for the first time an engineering mRNA PROTACs (m-PROTACs) strategy. This design combines von Hippel-Lindau (VHL) recruiting peptide encoding mRNA and POI-binding peptide encoding mRNA to form m-PROTAC and promote cellular POI degradation. We then performed proof-of-concept experiments using two m-PROTACs targeting two cancer-related proteins, estrogen receptor alpha and B-cell lymphoma-extra large protein. Our results demonstrated that m-PROTACs could successfully degrade the POIs in different cell lines and more effectively inhibit cell proliferation than the traditional p-PROTACs. Moreover, the in vivo experiment demonstrated that m-PROTAC led to significant tumor regression in the 4T1 mouse xenograft model. This finding highlights the enormous potential of m-PROTAC as a promising approach for targeted protein degradation therapy. We developed mRNA proteolysis-targeting chimeras (PROTACs), a novel type of PROTACs, which incorporate mRNAs encoding E3 ligase recruiting peptide ligand and protein of interest (POI)-binding peptide ligand to promote cellular POI degradation. For the first time, we demonstrated that the encoding peptide PROTACs could degrade POIs and inhibit cell proliferation more effectively than the traditional peptide PROTACs, indicating their tremendous potential for targeted protein degradation therapy. image

Inducible Degradation of Oncogenic Nucleolin Using an Aptamer-Based PROTAC

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Development of a novel PROTAC using the nucleic acid aptamer as a targeting ligand for tumor selective degradation of nucleolin

Constructing a warhead of PROTAC with aptamer for tumor-selective degradation of nucleolin

Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy

Small Molecule PROTACs in Targeted Therapy: an Emerging Strategy to Induce Protein Degradation.

Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation

Stimuli-activatable PROTACs for precise protein degradation and cancer therapy

Cooperatively Designed Aptamer-PROTACs for Spatioselective Degradation of Nucleocytoplasmic Shuttling Protein for Enhanced Combinational Therapy

Bioorthogonal PROTAC Prodrugs Enabled by On-Target Activation

Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation

PROTAC: An Effective Targeted Protein Degradation Strategy for Cancer Therapy

In Vivo Target Protein Degradation Induced by PROTACs Based on E3 Ligase DCAF15

Alkenyl Oxindole is a Novel PROTAC Moiety That Recruits the CRL4DCAF11 E3 Ubiquitin Ligase Complex for Targeted Protein Degradation

Addressing the Enzyme-independent tumor-promoting function of NAMPT via PROTAC-mediated degradation

Degradation of intrinsically disordered proteins using proteolysis targeting nanobody conjugate

Restraining the power of Proteolysis Targeting Chimeras in the cage: A necessary and important refinement for therapeutic safety

Destruction of DNA‐Binding Proteins by Programmable Oligonucleotide PROTAC (O'PROTAC): Effective Targeting of LEF1 and ERG

PROTACs technology for targeting non-oncoproteins: Advances and perspectives

The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination.

mRNA PROTACs: engineering PROTACs for high-efficiency targeted protein degradation